Anan G, Hirose T, Kikuchi D, Takahashi C, Endo A, Ito H, et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res. 2022;186:106524. https://doi.org/10.1016/j.phrs.2022.106524.

Article  CAS  PubMed  Google Scholar 

Anan G, Kikuchi D, Hirose T, Ito H, Nakayama S, Mori T. Impact of sodium-glucose cotransporter-2 inhibitors on urolithiasis. Kidney Int Rep. 2023;8:925–8. https://doi.org/10.1016/j.ekir.2023.01.034.

Article  PubMed  PubMed Central  Google Scholar 

Tanaka A, Node K. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. J Cardiol. 2017;69:501–7. https://doi.org/10.1016/j.jjcc.2016.10.019.

Article  PubMed  Google Scholar 

Committee on the proper use of SGLT2 inhibitors. Recommendations on the proper use of SGLT2 inhibitors. Diabetol Int. 2020;11:1–5. https://doi.org/10.1007/s13340-019-00415-8

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306. https://doi.org/10.1056/NEJMoa1811744.

Article  CAS  PubMed  Google Scholar 

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34. https://doi.org/10.1056/NEJMoa1515920.

Article  CAS  PubMed  Google Scholar 

Directors of the JCS and JDS. Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and pre-diabetes: a consensus statement jointed from the Japanese circulation society and the Japan diabetes society; Nankodo Co., Ltd. 2020:46–50.

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148–58. https://doi.org/10.1001/jamacardio.2020.4511.

Article  PubMed  Google Scholar 

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11:1020–76. https://doi.org/10.1111/jdi.13306.

Article  PubMed  PubMed Central  Google Scholar 

Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, et al. A consensus statement from the Japan diabetes society: a proposed algorithm for pharmacotherapy in people with type 2 diabetes. J Diabetes Investig. 2023;14:151–64. https://doi.org/10.1111/jdi.13960.

Article  PubMed  Google Scholar 

Nojiri S, Itoh H, Kasai T, Fujibayashi K, Saito T, Hiratsuka Y, et al. Comorbidity status in hospitalized elderly in Japan: analysis from national database of health insurance claims and specific health checkups. Sci Rep. 2019;9:20237. https://doi.org/10.1038/s41598-019-56534-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsokawa CSH, Kawamori R. Trends in prescriptions of diabetes medications: a 10-year review among specialists. Pract Diabetes. 2022;39:466–72.

Google Scholar 

Bouchi R, Sugiyama T, Goto A, Imai K, Ihana-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13:280–91. https://doi.org/10.1111/jdi.13636.

Article  CAS  PubMed  Google Scholar 

Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T. Characteristics of patients with diabetes initiating sodium glucose co-transporter-2 inhibitors (SGLT2i): real-world results from three administrative databases in Japan. Diabetes Ther. 2019;10:549–62. https://doi.org/10.1007/s13300-019-0577-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi H, Suganuma Y, Ohno T, Nishimura R. Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2022;13(4):606–14. https://doi.org/10.1007/s13340-022-00577-y.

Article  PubMed  PubMed Central  Google Scholar 

AstraZeneca Pharmaceuticals LP. Forxiga® (Dapagliflozin) Prescribing Information. Available online: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/670227_3969019F1027_2_14. Accessed on 15 April 2025 (in Japanese).

Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190–8. https://doi.org/10.31662/jmaj.2021-0189.

Article  PubMed  PubMed Central  Google Scholar 

Ministry of Health, Labour and Welfare, Japan. Universal Health Insurance System. Available Online: https://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01a.pdf. Accessed on 5 August 2024 (in Japanese).

Hashimoto Y, Okada A, Matsui H, Yasunaga H, Aihara M, Obata R. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. Jpn J Ophthalmol. 2023;67:109–18. https://doi.org/10.1007/s10384-022-00969-2.

Article  CAS  PubMed  Google Scholar 

Koto R, Nakajima A, Miwa T, Sugimoto K. Multimorbidity, polypharmacy, severe hypoglycemia, and glycemic control in patients using glucose-lowering drugs for type 2 diabetes: a retrospective cohort study using health insurance claims in Japan. Diabetes Ther. 2023;14:1175–92. https://doi.org/10.1007/s13300-023-01421-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Satoh M, Murakami T, Obara T, Metoki H. Time-series analysis of blood pressure changes after the guideline update in 2019 and the coronavirus disease pandemic in 2020 using Japanese longitudinal data. Hypertens Res. 2022;45:1408–17. https://doi.org/10.1038/s41440-022-00961-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishioka Y, Takeshita S, Kubo S, Myojin T, Noda T, Okada S, et al. Appropriate definition of diabetes using an administrative database: a cross-sectional cohort validation study. J Diabetes Investig. 2022;13(2):249–55. https://doi.org/10.1111/jdi.13641.

Article  PubMed  Google Scholar 

Ryotaro Bouchi TK, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, Suzuki R, Toshimasa Y. JDS Committee on Consensus Statement Development. A consensus statement from the Japan diabetes society: a proposed algorithm for pharmacotherapy in people with type 2 diabetes. J Jpn Diabetes Soc. 2022;65:419–34.

Han SJ, Ha KH, Lee N, Kim DJ. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab. 2021;23:682–91. https://doi.org/10.1111/dom.14261.

Article  CAS  PubMed  Google Scholar 

Patorno E, Pawar A, Bessette LG, Kim DH, Dave C, Glynn RJ, et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021;44:826–35. https://doi.org/10.2337/dc20-1464.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ministry of Health, Labour and Welfare. Statistics on Diabetes in Japan, Report of the Working Group on the Revision of the Calculation Methods for the "Average Consultation Interval" and the "Total Number of Patients" in Patient Survey. https://www.mhlw.go.jp/content/10700000/000820141.pdf. Accessed on 11 July 2025 (in Japanese)

Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab. 2014;16(12):1247–56. https://doi.org/10.1111/dom.12379.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):e002758. https://doi.org/10.1136/bmjopen-2013-002758.

Article  PubMed  PubMed Central  Google Scholar 

Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, Komuro I, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–7. https://doi.org/10.1536/ihj.54.93.

Article  PubMed  Google Scholar 

Kubota S, Haraguchi T, Kuwata H, Seino Y, Murotani K, Tajima T, et al. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan. J Diabetes Investig. 2023;14(1):67–74. https://doi.org/10.1111/jdi.13921.

Article  CAS  PubMed  Google Scholar 

Act on securing medical care for the elderly. https://laws.e-gov.go.jp/law/357AC0000000080?utm_source. Accessed on 18 April 2025 (in Japanese)

Report of the study working group on the elderly and aging society by the Japan gerontological society. https://jpn-geriat-soc.or.jp/info/important_info/pdf/20240614_01_01.pdf. Accessed on 18 April 2025 (in Japanese)

Ministry of Health, Labour and Welfare. Differences in medical aspects between older elderly and younger elderly [Presentation]. Working Group on the Health System Structure Reform Draft, 20th Social Security Council, Medical Insurance Subcommittee; 2005. https://www.mhlw.go.jp/content/12404000/000528279.pdf. Accessed on 17 August 2025 (in Japanese)

Johannes CB, Ziemiecki R, Pladevall-Vila M, Ebert N, Kovesdy CP, Thomsen RW, et al. Clinical profile and treatment adherence in patients with type 2 diabetes and chronic kidney disease who initiate an SGLT2 inhibitor: a multi-cohort study. Diabetes Ther. 2025;16:205–26.